We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A group of investment funds sued Allergan, accusing the company of artificially inflating its stock by conspiring with other manufacturers of generic drugs. Read More
Federal administrators of the Medicare Part D prescription-drug program should expand their oversight of opioid prescriptions and focus their surveillance of potential drug abuse more tightly on opioids, the U.S. Government Accountability Office said in a report. Read More
Allergan drew bipartisan fire from U.S. House members considering issues raised by the company’s innovative scheme to shield its patents on the blockbuster dry-eye drug Restasis from challenges before the Patent Trial and Appeal Board. Read More
A Stanford law professor said the president already has the authority to provide for administration of unapproved drugs to military personnel — a power similar to that proposed for the Department of Defense in pending federal legislation that has raised alarms in Congress. Read More